Ever Fortune. AI (6841) reported revenue of NT$36.7 million for Oct 2026, -1.0% year on year and -0.7% from the previous month. Revenue for Jan–Oct 2026 was NT$310.9 million (+15.5% year on year).
In Oct 2026, it ranked No. 111 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$36.7 million | -1.0% | -0.7% |
| Sep 2026 | NT$37 million | +65.3% | -7.5% |
| Aug 2026 | NT$40 million | +86.0% | +33.9% |
| Jul 2026 | NT$29.9 million | +2.5% | +6.8% |
| Jun 2026 | NT$27.9 million | +6.1% | -24.8% |
| May 2026 | NT$37.2 million | +12.9% | +12.6% |
| Apr 2026 | NT$33 million | +17.6% | +9.8% |
| Mar 2026 | NT$30.1 million | +15.0% | +153.6% |
| Feb 2026 | NT$11.9 million | -53.0% | -56.8% |
| Jan 2026 | NT$27.4 million | +34.6% | -39.1% |
| Dec 2025 | NT$45.1 million | +36.3% | -25.1% |
| Nov 2025 | NT$60.2 million | +55.2% | +62.3% |
| Oct 2025 | NT$37.1 million | +7.3% | +65.8% |
| Sep 2025 | NT$22.4 million | -31.5% | +4.0% |
| Aug 2025 | NT$21.5 million | -37.8% | -26.3% |
| Jul 2025 | NT$29.1 million | +4.7% | +10.7% |
| Jun 2025 | NT$26.3 million | -7.0% | -20.1% |
| May 2025 | NT$32.9 million | -12.7% | +17.3% |
| Apr 2025 | NT$28.1 million | +12.6% | +7.4% |
| Mar 2025 | NT$26.1 million | +23.7% | +3.6% |
| Feb 2025 | NT$25.2 million | +23.2% | +23.8% |
| Jan 2025 | NT$20.4 million | +81.0% | -38.3% |
| Dec 2024 | NT$33.1 million | +90.4% | -14.7% |
| Nov 2024 | NT$38.8 million | +146.8% | +12.2% |
| Oct 2024 | NT$34.5 million | +179.8% | +5.9% |
Jan–Oct 2026 cumulative: NT$310.9 million (+15.5% YoY)
Other Biotech & Medical companies
Compare with peers: Ever Fortune. AI vs PEC / Ever Fortune. AI vs Lotus Pharm / Ever Fortune. AI vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16